Roth Capital Has Negative Outlook of BRTX FY2028 Earnings

BioRestorative Therapies, Inc. (NASDAQ:BRTX) – Investment analysts at Roth Capital decreased their FY2028 earnings per share estimates for shares of BioRestorative Therapies in a report released on Thursday, November 14th. Roth Capital analyst J. Aschoff now forecasts that the company will post earnings of $5.40 per share for the year, down from their previous estimate of $5.43. The consensus estimate for BioRestorative Therapies’ current full-year earnings is ($1.76) per share.

Separately, Roth Mkm boosted their price objective on BioRestorative Therapies from $15.00 to $18.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th.

BioRestorative Therapies Trading Down 4.0 %

Shares of NASDAQ BRTX opened at $1.45 on Friday. The company has a market cap of $10.03 million, a PE ratio of -0.95 and a beta of 63.40. The company has a 50-day moving average of $1.63 and a two-hundred day moving average of $1.60. BioRestorative Therapies has a 1-year low of $1.03 and a 1-year high of $3.67.

BioRestorative Therapies (NASDAQ:BRTX) last announced its quarterly earnings results on Tuesday, November 12th. The company reported ($0.13) EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.22. The firm had revenue of $0.23 million during the quarter, compared to analysts’ expectations of $0.30 million. BioRestorative Therapies had a negative net margin of 2,697.08% and a negative return on equity of 98.49%.

About BioRestorative Therapies

BioRestorative Therapies, Inc, a life sciences company, focuses on the development of regenerative medicine products and therapies using cell and tissue protocols primarily involving adult stem cells. The company's two core developmental programs relate to the treatment of disc/spine disease and metabolic disorders.